The in vivo immunomodulatory and synergistic anti-tumor activity of thymosin α1-thymopentin fusion peptide and its binding to TLR2.

Abstract

In the present study, the immunomodulatory and synergistic anti-tumor activity of thymosin α1-thymopentin fusion peptide (Tα1-TP5) was investigated in vivo. In addition, the potential receptor of Tα1-TP5 was investigated by surface plasmon resonance (SPR) binding studies. It was found that Tα1-TP5 (305 μg/kg) alleviated immunosuppression induced by hydrocortisone (HC). Tα1-TP5 (305 μg/kg) combined with cyclophosphamide (CY) had a better tumor growth inhibitory effect than CY alone. Furthermore, Tα1-TP5 had a higher affinity (KD=6.84 μmol/L) to toll-like receptor 2 (TLR2) than Tα1 (K(D)=35.4 μmol/L), but its affinity was not significantly different from that of TP5. The results of our present work indicate that Tα1-TP5 can possibly be developed as a new immunomodulatory agent.

• Authors: Juan Li, Yanna Cheng, Xinke Zhang, Lei Zheng, Zhen Han, Pingli Li, Yuliang Xiao, Qian Zhang, Fengshan Wang
• Journal: Cancer letters (Cancer Lett) Vol. 337 Issue 2 Pg. 237-47 (Sep 01 2013) ISSN: 1872-7980 [Electronic] Ireland
• PMID: 23684552 (Publication Type: Journal Article)
• Copyright: Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Chemical References

• Antineoplastic Agents
• Antineoplastic Agents, Alkylating
• B7-2 Antigen
• Cd86 protein, mouse
• Histocompatibility Antigens Class I
• Immunologic Factors
• Immunosuppressive Agents
• Tlr2 protein, mouse
• Toll-Like Receptor 2
• Thymosin
• Interferon-gamma
• Cyclophosphamide
• Thymopentin
• Thymalfasin
• Hydrocortisone

Topics

• Animals
• Antineoplastic Agents (immunology, metabolism, pharmacology)
• Antineoplastic Agents, Alkylating (pharmacology)
• Antineoplastic Combined Chemotherapy Protocols (pharmacology)
• Atrophy
• B7-2 Antigen (metabolism)
• Cyclophosphamide (pharmacology)
• Drug Synergism
• Histocompatibility Antigens Class I (metabolism)
• Hydrocortisone (pharmacology)
• Immunologic Factors (metabolism, pharmacology)
• Immunosuppressive Agents (pharmacology)
• Interferon-gamma (blood)
• Male
• Melanoma, Experimental (drug therapy, immunology, pathology)
• Mice
• Mice, Inbred BALB C
• Mice, Inbred C57BL
• Protein Binding
• Skin Neoplasms (drug therapy, immunology, pathology)
• Surface Plasmon Resonance
• Thymalfasin
• Thymocytes (drug effects, immunology, pathology)
• Thymopentin (immunology, metabolism, pharmacology)
• Thymosin (analogs & derivatives, immunology, metabolism, pharmacology)
• Thymus Gland (drug effects, immunology, pathology)
• Time Factors
• Toll-Like Receptor 2 (metabolism)
• Tumor Burden (drug effects)